-
Something wrong with this record ?
Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression
I Frydrych, P Mlejnek, P Dolezel
Language English Country Great Britain
Document type Research Support, Non-U.S. Gov't
Grant support
NR9482
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
- MeSH
- Apoptosis drug effects MeSH
- Fusion Proteins, bcr-abl analysis MeSH
- K562 Cells MeSH
- Cyclosporine pharmacology MeSH
- Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors MeSH
- Glutathione analysis MeSH
- Glutathione Disulfide analysis MeSH
- Imidazoles pharmacology MeSH
- Humans MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 analysis physiology MeSH
- Piperazines pharmacology MeSH
- Antineoplastic Agents pharmacology MeSH
- Pyridines pharmacology MeSH
- Pyrimidines pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
The effect of cyclosporin A (CsA) on imatinib treated Bcr-Abl positive K562 cells was studied. Similarly to other authors we found that imatinib induced apoptosis and erythroid differentiation in K562 cells. While its low concentrations induced predominantly erythroid differentiation, higher concentrations induced apoptosis. We found that CsA significantly potentiated cytotoxic effects of imatinib. A detailed analysis revealed that CsA shifted the balance between differentiation and apoptosis in favour of apoptosis. Our findings indicated that the observed effect of CsA was mediated neither through inhibition of ERK1/2 (extracellular signal-regulated kinases 1/2), nor through inhibition of p38 MAPK. We further observed that CsA might sensitise cells to apoptosis due to a changed cellular redox status as combined treatment of cells with imatinib and CsA resulted in a dramatic decrease of the ratio between reduced (GSH) and oxidised (GSSG) glutathione GSH/GSSG and in a significant suppression of thioredoxin reductase enzymatic activity. Our results indicated that K562 cells did not express detectable level of P-glycoprotein (P-gp). In addition, CsA did not affect significantly the intracellular level of imatinib. Therefore we excluded the possibility that CsA increased sensitivity of cells to imatinib by the inhibition of P-gp-mediated drug efflux or by another mechanism involving modulation of intracellular drug concentration.
- 000
- 03115naa a2200409 a 4500
- 001
- bmc12009167
- 003
- CZ-PrNML
- 005
- 20140717082728.0
- 008
- 120319s2009 xxk eng||
- 009
- AR
- 040 __
- $d ABA008 $a ABA008 $b cze
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Frydrych, Ivo $7 xx0169396 $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc
- 245 10
- $a Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression / $c I Frydrych, P Mlejnek, P Dolezel
- 520 9_
- $a The effect of cyclosporin A (CsA) on imatinib treated Bcr-Abl positive K562 cells was studied. Similarly to other authors we found that imatinib induced apoptosis and erythroid differentiation in K562 cells. While its low concentrations induced predominantly erythroid differentiation, higher concentrations induced apoptosis. We found that CsA significantly potentiated cytotoxic effects of imatinib. A detailed analysis revealed that CsA shifted the balance between differentiation and apoptosis in favour of apoptosis. Our findings indicated that the observed effect of CsA was mediated neither through inhibition of ERK1/2 (extracellular signal-regulated kinases 1/2), nor through inhibition of p38 MAPK. We further observed that CsA might sensitise cells to apoptosis due to a changed cellular redox status as combined treatment of cells with imatinib and CsA resulted in a dramatic decrease of the ratio between reduced (GSH) and oxidised (GSSG) glutathione GSH/GSSG and in a significant suppression of thioredoxin reductase enzymatic activity. Our results indicated that K562 cells did not express detectable level of P-glycoprotein (P-gp). In addition, CsA did not affect significantly the intracellular level of imatinib. Therefore we excluded the possibility that CsA increased sensitivity of cells to imatinib by the inhibition of P-gp-mediated drug efflux or by another mechanism involving modulation of intracellular drug concentration.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a protinádorové látky $x farmakologie $7 D000970
- 650 02
- $a apoptóza $x účinky léků $7 D017209
- 650 02
- $a cyklosporin $x farmakologie $7 D016572
- 650 02
- $a extracelulárním signálem regulované MAP kinasy $x antagonisté a inhibitory $7 D048049
- 650 02
- $a bcr-abl fúzní proteiny $x analýza $7 D016044
- 650 02
- $a glutathion $x analýza $7 D005978
- 650 02
- $a glutathiondisulfid $x analýza $7 D019803
- 650 02
- $a lidé $7 D006801
- 650 02
- $a imidazoly $x farmakologie $7 D007093
- 650 02
- $a buňky K562 $7 D020014
- 650 02
- $a P-glykoprotein $x analýza $x fyziologie $7 D020168
- 650 02
- $a piperaziny $x farmakologie $7 D010879
- 650 02
- $a pyridiny $x farmakologie $7 D011725
- 650 02
- $a pyrimidiny $x farmakologie $7 D011743
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mlejnek, Petr, $d 1963- $7 xx0023808
- 700 1#
- $a Doležel, Petr. $7 xx0317513
- 773 0_
- $t Toxicology in Vitro $p Toxicol In Vitro $g Roč. 23, č. 8 (2009), s. 1482-1490 $x def $w MED00004536
- 773 0_
- $p Toxicol In Vitro $g 23(8):1482-90, 2009 Dec
- 910 __
- $a ABA008 $b x $y 4 $z 0
- 990 __
- $a 20120319150915 $b ABA008
- 991 __
- $a 20140717083030 $b ABA008
- 999 __
- $a ok $b bmc $g 902390 $s 766073
- BAS __
- $a 3
- BMC __
- $a 2009 $b 23 $c 8 $d 1482-1490 $i def $m Toxicology in vitro $x MED00004536
- GRA __
- $a NR9482 $p MZ0
- LZP __
- $a 2012-1Q10/